Industry Briefs: June 4, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AMRI Burlington has been contracted as an aseptic fill manufacturer for the market introduction of Cardium Therapeutics’s and its subsidiary, Tissue Repair Company’s, wound-care product Excellagen. Read More
Baxter International has entered into an agreement with Chatham Therapeutics for development and commercialization of Chatham’s Factor IX hemophilia B gene-therapy treatment. Read More
Bayer HealthCare has formed a partnership with Covance for clinical drug development, including R&D services related to Phase II–IV clinical studies and central laboratory services. Read More
Bristol-Myers Squibb has partnered with 10 cancer-research centers in immuno-oncology. Read More
Catalent Pharma Solutions has signed a definitive agreement to sell its US commercial-packaging operations based in Philadelphia, Pennsylvania, and Woodstock, Illinois, to a company affiliated with Frazier Healthcare. The transaction is subject to certain closing conditions and is expected to close in the next few months. Read More
Forest Laboratories and Nabriva Therapeutics have entered into a $25-million agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Read More
Genmab and Novartis have agreed to use Genmab’s DuoBody technology platform to create and develop bispecific antibodies. Read More
JHP Pharmaceuticals has entered into an agreement with an undisclosed pharmaceutical company to produce the clinical and commercial supply of an innovative injectable used in the cardiovascular setting. Read More
Mylan has received FDA approval to launch a generic version of Pfizer’s Lipitor (atorvastatin calcium). Read More
WuXi PharmTech has commented on the conviction of a former employee for the theft of Merck compounds. Read More
People News
BioStorage Technologies has appointed Kristina Robson as senior director of comprehensive solutions. Read More
William G. Kaelin, Jr. has been elected to Eli Lilly's board of directors. Read More
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
